Should endovascular therapy for cerebral vasospasm coincide with hypervolemic-hypertensive therapy (HT) in aneurysmal subarachnoid hemorrhage (SAH)?
In patients suffering from SAH, cerebral vasospasm is a major cause of morbidity and mortality from multifocal cerebral infaretion. Hypervolemic-hypertensive therapy is considered the cornerstone of the medical management and generally the first line approach. The therapeutic role of intra-arterial infusion of papaverine and balloon angioplasty has been established as an alternative therapy. The timing of neuroradiological intervention is unknown.
Related Questions
- Should endovascular therapy for cerebral vasospasm coincide with hypervolemic-hypertensive therapy (HT) in aneurysmal subarachnoid hemorrhage (SAH)?
- Does eicosapentaenoic acid (EPA) inhibit cerebral vasospasm in patients after aneurysmal subarachnoid hemorrhage?
- Is antifibrinolytic therapy beneficial after aneurysmal subarachnoid hemorrhage?